

---

**LEVIATHAN NATURAL PRODUCTS INC.**  
(Formerly Leviathan Cannabis Group Inc.)

**CONSOLIDATED FINANCIAL STATEMENTS**

**Years Ended August 31, 2020 and August 31, 2019**  
(in Canadian Dollars)

---

### **Management's Responsibility for Financial Reporting**

The accompanying consolidated financial statements for the Company have been prepared by management in accordance with the International Financial Reporting Standards. These consolidated financial statements contain estimates based on managements judgement. Management maintains an appropriate system of internal controls to provide reasonable assurance that transactions are authorized assets safeguarded, and proper records maintained.

The Audit Committee and Board of Directors reviews the results of the annual audit and the consolidated financial statements prior to submitting the consolidated financial statements to the Board for approval.

The Company's auditors, MNP LLP, are appointed by the shareholders to conduct an audit and their report follows.

Signed: "*Martin Doane*"

Chief Executive Officer

Signed: "*Jayne Beckwith*"

Chief Financial Officer

Toronto, Ontario

December 23, 2020

To the Shareholders of Leviathan Natural Products Inc. (formerly Leviathan Cannabis Group Inc.):

## Opinion

We have audited the consolidated financial statements of Leviathan Natural Products Inc. (formerly Leviathan Cannabis Group Inc.) and its subsidiaries (the "Company"), which comprise the consolidated statements of financial position as at August 31, 2020 and August 31, 2019, and the consolidated statements of operations and comprehensive loss, changes in shareholders' equity (deficit) and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at August 31, 2020 and August 31, 2019, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with International Financial Reporting Standards.

## Basis for Opinion

We conducted our audits in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audits of the consolidated financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## Material Uncertainty Related to Going Concern

We draw attention to Note 1 in the consolidated financial statements, which indicates that the Company incurred a net loss of \$3,028,801 during the year ended August 31, 2020 and, as of that date, the Company had a deficit of \$36,676,401 and a working capital deficiency of \$5,483,720. As stated in Note 1, these events or conditions, along with other matters as set forth in Note 1, indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

## Other Information

Management is responsible for the other information. The other information comprises Management's Discussion and Analysis.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audits of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audits or otherwise appears to be materially misstated. We obtained Management's Discussion and Analysis prior to the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## **Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements**

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Consolidated Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audits and significant audit findings, including any significant deficiencies in internal control that we identify during our audits.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

The engagement partner on the audit resulting in this independent auditor's report is Andrew Kevin Spidle.

Mississauga, Ontario

December 23, 2020

*MNP LLP*

Chartered Professional Accountants

Licensed Public Accountants

**LEVIATHAN NATURAL PRODUCTS INC.**  
(Formerly Leviathan Cannabis Group Inc.)  
**CONSOLIDATED STATEMENTS OF FINANCIAL POSITION**  
**AS AT AUGUST 31, 2020 AND 2019**  
(Amounts Expressed in Canadian dollars)

	2020	2019
<b>Assets</b>		
<b>Current Assets</b>		
Cash	\$ 24,840	\$ 922,213
Other Receivable	20,506	2,224
Investment	25,000	25,000
Prepaid Expenses	107,275	66,619
HST Recoverable	528,919	417,864
	<u>706,540</u>	<u>1,433,920</u>
Investment Property (Note 5)	3,984,390	-
Property, Plant & Equipment (Note 6)	5,192,617	3,824,049
	<u>\$ 9,883,547</u>	<u>\$ 5,257,969</u>
<b>Liabilities</b>		
<b>Current Liabilities</b>		
Accounts Payable & Accrued Liabilities	778,249	407,007
Deferred Revenue	581,853	-
Current Portion of Long-Term Debt	4,830,158	-
	<u>6,190,260</u>	<u>407,007</u>
Long-Term Debt (Note 7)	5,295,110	3,717,089
	<u>11,485,370</u>	<u>4,124,096</u>
<b>Non-Controlling Interest</b> (Note 9)	(244,615)	(33,420)
<b>Equity</b>		
Share Capital (Note 8(a))	31,138,597	31,138,597
Warrants (Note 8(c))	2,477,380	2,477,380
Options (Note 8(b))	1,963,008	3,514,465
Accumulated Deficit	(36,676,401)	(35,953,825)
Accumulated Other Comprehensive (Loss) Income	(259,792)	(9,324)
	<u>(1,357,208)</u>	<u>1,167,293</u>
Total Shareholders' Equity and non-controlling interest	(1,601,823)	1,133,873
	<u>\$ 9,883,547</u>	<u>\$ 5,257,969</u>

*Going Concern (Note 1), Contingency (Note 14), Subsequent Events (Note 15)*

*The accompanying notes are an integral part of these consolidated financial statements.*

**LEVIATHAN NATURAL PRODUCTS INC.**

(Formerly Leviathan Cannabis Group Inc.)

**CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)**

**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

(Amounts Expressed in Canadian dollars)

	Number of Shares	Share Capital	Shares to be Issued	Warrants	Options	Deficit	Accumulated Other Comprehensive (Loss)/Income	Total Shareholders' Equity	Non- Controlling Interest	Total Equity and Non- Controlling Interest
<b>Balance, August 31, 2018</b>	<b>90,771,601</b>	<b>42,415,746</b>	<b>25,000</b>	<b>1,822,000</b>	<b>5,351,347</b>	<b>(9,615,134)</b>	-	<b>39,998,959</b>	-	<b>39,998,959</b>
Private Placement, Net of Issue Costs (Note 8(a))	3,972,002	1,330,621	(25,000)	655,380	-	-	-	1,961,001	-	1,961,001
Cancellation of Common Stock (Note 4 and Note 8(a))	(10,000,000)	(12,607,770)	-	-	-	-	-	(12,607,770)	-	(12,607,770)
Vesting of Stock Options (Note 8(b))	-	-	-	-	353,054	-	-	353,054	-	353,054
Stock Options Expired (Note 8(b))	-	-	-	-	(2,189,936)	2,189,936	-	-	-	-
Net and Comprehensive Loss for the Year	-	-	-	-	-	(28,528,627)	(9,324)	(28,537,951)	(33,420)	(28,571,371)
<b>Balance, August 31, 2019</b>	<b>84,743,603</b>	<b>31,138,597</b>	<b>-</b>	<b>2,477,380</b>	<b>3,514,465</b>	<b>(35,953,825)</b>	<b>(9,324)</b>	<b>1,167,293</b>	<b>(33,420)</b>	<b>1,133,873</b>
Vesting of Stock Options (Note 8(b))	-	-	-	-	60,354	-	-	60,354	-	60,354
Stock Options Expired (Note 8(b))	-	-	-	-	(1,611,811)	1,611,811	-	-	-	-
Benefit of Shareholder Loan	-	-	-	-	-	483,219	-	483,219	-	483,219
Net and Comprehensive (Loss)/Income for the Period	-	-	-	-	-	(2,817,606)	(250,468)	(3,068,074)	(211,195)	(3,279,269)
<b>Balance, August 31, 2020</b>	<b>84,743,603</b>	<b>31,138,597</b>	<b>-</b>	<b>2,477,380</b>	<b>1,963,008</b>	<b>(36,676,401)</b>	<b>(259,792)</b>	<b>(1,357,208)</b>	<b>(244,615)</b>	<b>(1,601,823)</b>

The accompanying notes are an integral part of these consolidated financial statements.

**LEVIATHAN NATURAL PRODUCTS INC.**

(Formerly Leviathan Cannabis Group Inc.)

**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS****FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

(Amounts Expressed in Canadian dollars)

	2020	2019
<b>Revenue</b>		
Branding Service	\$ -	\$ 118,503
Rent	72,732	-
	72,732	118,503
<b>Expenses</b>		
Salaries, Wages & Consulting Fees (Note 11)	\$ 1,326,776	\$ 1,614,050
Interest (Note 7)	890,945	307,054
Professional Fees	287,744	494,786
Office & General	358,455	276,150
Foreign Exchange (Gain) Loss	4,489	375
Travel	31,313	66,446
Investor Relations & Fees	52,332	150,328
Share Based Compensation (Note 8(b))	60,354	353,054
Rent	19,626	69,705
Utilities	93,284	10,539
Amortization (Note 6)	42,578	3,409
Marketing	5,890	160,193
Bad Debt	-	68,875
Fair value adjustment on investment property (Note 6)	(7,253)	-
Loss on Disposal of Assets	-	1,203,616
Impairment of Assets (Note 4)	-	23,901,970
Recovery	(65,000)	-
	3,101,533	28,680,550
	-	-
<b>Net Loss</b>	<b>\$ (3,028,801)</b>	<b>\$ (28,562,047)</b>
<b>Other Comprehensive Loss</b>		
Unrealized foreign exchange on net investments in foreign operations	(211,156)	(2,284)
Foreign Exchange Translation	(39,312)	(7,040)
<b>Net Comprehensive Loss</b>	<b>\$ (3,279,269)</b>	<b>\$ (28,571,371)</b>
<b>Net Loss Attributable to:</b>		
Non-controlling Interest (Note 9)	\$ (211,195)	\$ (33,420)
Shareholders of the Company	\$ (2,817,606)	\$ (28,528,627)
	<b>\$ (3,028,801)</b>	<b>\$ (28,562,047)</b>
<b>Weighted Average Number of Common Shares Outstanding – Basic and Diluted (Note 9)</b>	<b>84,743,603</b>	<b>84,743,603</b>
<b>Basic and Fully Diluted Loss per Share</b>	<b>\$ (0.03)</b>	<b>\$ (0.34)</b>

*The accompanying notes are an integral part of these consolidated financial statements.*



**LEVIATHAN NATURAL PRODUCTS INC.**

(Formerly Leviathan Cannabis Group Inc.)

**CONSOLIDATED STATEMENTS OF CASH FLOWS****FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

(Amounts Expressed in Canadian dollars)

	2020	2019
<b>Cash Flow from Operating Activities</b>		
Net Loss	(3,028,801)	(28,562,047)
Add-Back (Deduct) Non-Cash Items		
Amortization	42,578	3,409
Interest and accretion	890,945	327,053
Share Based Compensation	60,354	353,054
Rent revenue	(73,732)	-
Fair value adjustment on investment property	(7,253)	1,203,616
Impairment	-	23,901,970
Bad debt	-	68,875
Changes in Non-Cash Working Capital:		
Trade Receivable	-	(25,000)
Other Receivable	(18,282)	(2,224)
Prepaid Expenses	(40,656)	95,726
HST Recoverable	(111,055)	(228,877)
Accounts Payable & Accrued Liabilities	371,242	(339,570)
	(1,914,660)	(3,204,015)
<b>Cash Flow from Financing Activities</b>		
Lease payments	(39,377)	-
Colombia mortgage payments	(462,960)	-
Bridge loan	5,282,493	-
Repayment of interest	-	(60,000)
Private Placement, Net of Issue Costs	-	2,064,031
	4,780,156	2,004,031
<b>Cash Flow from Investing Activities</b>		
Advance to Pulse RX Inc.	-	(50,000)
Loans & Deposits	-	388,745
Purchase of property, plant & equipment	(3,699,704)	(1,084,741)
Disposal of property, plant & equipment	-	5,650
	(3,699,704)	(740,346)
<b>Increase (Decrease) in Cash</b>	<b>(834,208)</b>	<b>(1,940,330)</b>
<b>Effect of foreign exchange translation</b>	<b>(63,166)</b>	<b>(7,040)</b>
<b>Cash, Beginning of Year</b>	<b>922,213</b>	<b>2,869,583</b>
<b>Cash, End of Year</b>	<b>24,840</b>	<b>922,213</b>

*The accompanying notes are an integral part of these consolidated financial statements.*

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

## **1. NATURE OF BUSINESS AND GOING CONCERN**

### **Nature of Business**

Leviathan Natural Products Inc. (Formerly Leviathan Cannabis Group Inc.) (the "Company") is a cannabis focused, marketing services agency and is, through its subsidiaries, pursuing the goal of becoming a fully licensed cultivator, processor and distributor of cannabis and hemp products in Canada, United States & South America.

The Company is a publicly traded company incorporated and domiciled in Canada. The Company's registered office is Suite 116, 250 The Esplanade, Toronto, Ontario M5H 4J6. The Company's common shares are listed on the Canadian Securities Exchange (the "CSE") under the symbol EPIC.

### **Going Concern**

These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

During the year, there was a global outbreak of COVID-19 (coronavirus), which had a significant impact on businesses through restrictions put in place by federal, provincial, state and municipal governments regarding travel, business operations, and isolations/quarantine orders. At this time, it is unknown the extent of the impact the COVID-19 outbreak may have on the Company as this will depend on future developments that are highly uncertain and that cannot be predicted with confidence. These uncertainties arise from the inability to predict the ultimate geographic spread of the disease and the duration of the outbreak, including the duration of travel restrictions, business closures or disruptions and quarantine/isolation measures that are currently, or may be put, in place by Canada and other countries to fight the virus. While the extent of the impact is unknown, we anticipate that this outbreak may cause reduced customer demand, supply chain disruptions, staff shortages and increased government regulations, all of which may negatively impact the Company's business and financial condition. COVID-19 has not had a material adverse effect on the Company's operations given it is pre-revenue nor has it had an immediate impact on the Company's ability to lease its investment property in Ontario. The pandemic has had a limited effect on the construction phase of its operations in Tennessee. Understandably, vendors were slower to fulfill some orders because of supply chain disruptions. Consequently, time delays pushed back the intended start date by approximately six months.

For the year ended August 31, 2020, the Company reported a net loss of \$3,028,081 (2019 - \$28,562,047) and, as at August 31, 2020, had a deficit of \$36,676,401 (2019 - \$35,953,825) and a working capital deficiency of \$5,483,720 (2019 - working capital of \$1,026,913). Management has forecasted that the expected expenditure levels and contracted commitments will exceed the Company's net cash inflows and working capital for the fiscal year 2021 unless further financing is obtained. Additional sources of funding will be required to carry on operations and/or to realize on investment opportunities. The Company's future operations are dependent upon its ability to secure additional funds and generate product sales. While the Company is striving to achieve these plans, there is no assurance that these and other strategies will be realized, or such sources of funds will be available or obtained on favourable terms or obtained at all. Historically, the Company has obtained funding via the issuance of shares and warrants and short-term borrowings. If the Company cannot secure additional financing on terms that would be acceptable to it or otherwise generate product sales, the Company will have to consider additional strategic alternatives which may include, among other strategies, cost curtailments and delays of product launch, as well as seeking to license and/or divest assets or a merger, sale or liquidation of the Company. These material uncertainties may cast significant doubt on the Company's ability to continue as a going concern.

These consolidated financial statements do not reflect the adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for these condensed consolidated financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported revenues and expenses, and the consolidated statements of financial position classifications used.

## **2. SIGNIFICANT ACCOUNTING POLICIES**

### **(a) Statement of compliance**

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and the interpretations of the IFRS Interpretations Committee ("IFRIC").

These consolidated financial statements were approved by the Board of Directors on December 21, 2020.

### **(b) Basis of presentation and consolidation**

These consolidated financial statements have been prepared on a historical cost basis except for certain financial instruments carried at fair value.

These consolidated financial statements include the accounts of the Company and its subsidiaries. Additional information on the Company's interest in subsidiaries is provided in Note 9.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**2. SIGNIFICANT ACCOUNTING POLICIES - continued**

**(c) Functional and presentation currency**

The consolidated financial statements of the Company are presented in Canadian dollars. The functional currency of the Company and its subsidiaries is the Canadian dollar, except for Leviathan US, which has a US dollar functional currency, and Grupo LCG SAS, which has a Colombian peso functional currency.

Transactions in currencies other than the functional currency are translated to the functional currency at the rate of exchange prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency rate of exchange prevailing at the consolidated statements of financial position date. Exchange gains and losses on settlement of transactions, and the translation of monetary assets and liabilities other than in functional currency are recorded in the consolidated statements of operations and comprehensive loss.

Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument to another entity. Financial assets and financial liabilities are recognized on the Statements of Financial Position at the time the Company becomes a party to the contractual terms and provisions of the financial instrument.

Financial assets

Non-derivative financial assets within the IFRS 9 are classified as “financial assets at fair value” (either as Fair Value through Other Comprehensive Income (“FVTOCI”) or as fair value through profit or loss (“FVTPL”)), and “financial assets at amortized costs” as appropriate. The Company determines the classification of its financial assets at initial recognition based on the Company’s business model and contractual terms of cash flows.

All financial assets are recognized initially at fair value plus, in the case of investments not at FVTPL, directly attributable transaction costs on the trade date at which the Company becomes a party to the contractual provisions of the instrument.

Where the fair values of financial assets recorded on the consolidated statement of financial position cannot be derived from active markets, they are determined using a variety of valuation techniques. The inputs to these models are derived from observable market data where possible, but where observable market data are not available, judgment is required to establish fair values.

Financial assets at FVTPL

Financial assets measured at FVTPL include financial assets management intends to sell and any derivative financial instrument that is not designated as a hedging instrument in a hedge relationship. Financial assets measured at FVTPL are carried at fair value in the consolidated statements of financial position with changes in fair value recognized in other income or expense in the consolidated statements of operations and comprehensive loss. The Company’s investment is designated at FVTPL.

Financial assets at FVTOCI

Financial assets measured at FVTOCI are non-derivative financial assets that are not held for trading and the Company has made an irrevocable election at the time of initial recognition to measure the assets at FVTOCI. After initial measurement, investments measured at FVTOCI are subsequently measured at fair value with unrealized gains or losses recognized in other comprehensive income or loss in the consolidated statements of operations and comprehensive loss. When the investment is sold, the cumulative gain or loss remains in accumulated other comprehensive income or loss and is not reclassified to profit or loss. The Company has no financial assets designated at FVTOCI.

Derecognition

A financial asset is derecognized when the contractual rights to the cash flows from the asset expire, or the Company transfers substantially all the risks and rewards of ownership of the asset.

Impairment of financial assets

The impairment model under IFRS 9 is applicable to financial assets measured at amortized cost where any expected future credit losses are provided for, irrespective of whether a loss event has occurred as at the reporting date. The Company’s only financial assets subject to impairment are amounts receivable and note receivable, which are measured at amortized cost. The Company has elected to apply the simplified approach to impairment as permitted by IFRS 9, which requires the expected lifetime loss to be recognized at the time of initial recognition of the receivable. An impairment loss is reversed in subsequent periods if the amount of the expected loss decreases and the decrease can be objectively related to an event occurring after the initial impairment was recognized. The Company has measured the lifetime expected credit losses taking into consideration historical credit loss experience and financial factors specific to debtors and other relevant factors.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**2. SIGNIFICANT ACCOUNTING POLICIES - continued**

**(d) Financial instruments - continued**

Financial liabilities

Non-derivative financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL as is the case for held for trading or derivative instruments, or the Company has opted to measure the financial liability at FVTPL. The Company's financial liabilities include accounts payable & accrued liabilities, purchase price payable, and long-term debt, which are each measured at amortized cost. All financial liabilities are recognized initially at fair value and in the case of loans and borrowings, net of directly attributable transaction costs.

Financial liabilities at amortized cost

After initial recognition, financial liabilities measured at amortized cost are subsequently measured at the end of each reporting period at amortized cost using the Effective Interest Rate ("EIR") method. Amortized cost is calculated by taking into account any discount or premium on acquisition and any fees or costs that are an integral part of the EIR. The EIR accretion is included in finance cost in the consolidated statements of earnings (loss).

Derecognition

A financial liability is derecognized when the obligation under the liability is discharged, cancelled or expires with any associated gains or losses reported in other income or expense in the consolidated statements of loss and comprehensive loss.

Determination of fair value

The Company has determined the estimated fair values of its financial instruments based on appropriate valuation methodologies; however, considerable judgment is required to develop these estimates. The Company classifies fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements of the fair value of financial assets and liabilities.

- Level one includes quoted prices in active markets for identical assets or liabilities.
- Level two includes inputs that are observable other than quoted prices included in level one.
- Level three includes inputs that are not based on observable market data.

The following table summarizes the classification of the Company's financial instruments:

<b>IFRS 9 Classification</b>	
<b>Financial assets</b>	
Cash	Amortized cost
Other receivable	Amortized cost
Investment	FVTPL
<b>Financial Liabilities</b>	
Accounts payable	Amortized cost
Long-term debt	Amortized cost

**(e) Revenue recognition**

Revenue is recognized when the services have been performed and collection of the receivable is reasonably assured. The Company may enter into sales agreements with customers that have multiple performance obligations. When an individual performance obligation within the agreement is satisfied, the relative fair value of the individual performance obligation is recognized as revenue.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**2. SIGNIFICANT ACCOUNTING POLICIES - continued**

**(f) Property, plant, and equipment**

Recognition and measurement

Items of property and equipment are measured at cost less accumulated amortization and accumulated impairment losses. When parts of an item of property, plant, and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. The costs of the day to day servicing of property, plant and equipment are recognized in the statement of net loss and comprehensive loss in the period in which they are incurred.

Amortization

Amortization is recognized in profit or loss over the estimated useful lives of each part of an item of property and equipment in a manner which most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows:

<b>Asset</b>	<b>Basis</b>	<b>Rate</b>
Land	N/A	N/A
Building	Declining Balance	4%
Equipment	Declining Balance	30%
Growing Equipment	Declining Balance	30%

Depreciation of the Company's buildings will begin when the facilities are ready for use.

**(g) Intangible assets**

Intangible assets are recorded at cost less any accumulated amortization and accumulated impairment losses. Intangible assets acquired through a business combination are measured at fair value at the acquisition date.

Amortization begins when assets become available for use. The estimated useful life, amortization method, and rate are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

**(h) Investment Property**

Investment properties are held to earn rental income or for capital appreciation, or both. A key characteristic of an investment property is that it generates cash flows largely independently of the other assets held by an entity. Investment properties are initially measured at cost including transaction costs. Transaction costs include various professional fees, land transfer tax and initial leasing commissions to bring the property up to the condition necessary for it to be capable of operating. Subsequent to initial recognition, investment properties are recorded at fair value and related gains or losses arising from changes in fair value are recognized in net comprehensive income in the period of change. The determination of fair value is based upon, among other things, rental income from current leases and other assumptions that market participants would use when pricing investment property under current market conditions. An investment property is derecognized when it has been disposed of or permanently withdrawn from use and no future economic benefit is expected from its disposal. Any gains or losses on the retirement or disposal of an investment property are recognized in the consolidated statement of operations and comprehensive income in the period of retirement or disposal. Gains or losses on the disposal of an investment property are determined as the difference between the net disposal proceeds and the carrying value of the asset on the date of disposal. All property operating expenses in the consolidated statements of operations and comprehensive income pertain to properties which earn rental income. Investment property may also be transferred if the Company changes its use to owner-occupied property in which case the carrying value is transferred to property, plant, and equipment.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**2. SIGNIFICANT ACCOUNTING POLICIES - continued**

**(i) Impairment of non-financial assets**

The carrying values of non-financial assets are assessed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may exceed its recoverable amount. Additionally, the carrying values of goodwill, indefinite life intangibles, and intangibles not yet ready for use are assessed for indications of impairment at the end of every financial reporting period. Events or changes in circumstances which may indicate impairment include: a significant change to the Company's operations, significant decline in performance, or a change in market conditions which adversely affect the Company. The recoverable amount is determined as the higher of the fair value less costs of disposal ("FVLCD") and its value in use ("VIU") based on discounted cash flows.

For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its FVLCD and its VIU. If the carrying amount of an asset exceeds its recoverable amount, an impairment charge is recognized immediately in profit or loss by the amount by which the carrying amount of the asset exceeds the recoverable amount. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the lesser of the revised estimate of recoverable amount, and the carrying amount that would have been recorded.

During the year ended August 31, 2019, the Company fully impaired its License in Progress (see Note 4) and partially impaired its Woodstock building (see Note 6).

**(j) Provisions**

A provision is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and the amount of the obligation can be reliably estimated. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability.

A provision for onerous contracts is recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract.

The Company had no material provisions as at August 31, 2020.

**(k) Share-based payment transactions**

The fair value of stock options granted to employees is recognized as an expense over the vesting period with a corresponding increase in equity. An individual is classified as an employee when the individual is an employee for legal or tax purposes (direct employee) or provides services similar to those performed by a direct employee, including directors of the Company.

The fair value is measured at grant date and recognized over the period during which the options vest. The fair value of the options granted is measured using the Black-Scholes option pricing model, incorporating the terms and conditions upon which the options were granted. At the end of each reporting period, the amount recognized as an expense is adjusted to reflect the actual number of share options that are expected to vest or actually vested.

**(l) Loss per share**

Basic loss per share is calculated using the weighted-average number of common shares outstanding during the period excluding contingently issuable or returnable shares. Diluted loss per share is computed using the treasury stock method. Stock options and warrants outstanding are not included in the computation of diluted loss per share if their inclusion would be anti-dilutive.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**2. SIGNIFICANT ACCOUNTING POLICIES - continued**

**(m) Significant accounting estimates, judgments, and assumptions**

The preparation of these financial statements requires management to make certain estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual outcomes could differ from these estimates. These financial statements include estimates that, by their nature, are uncertain. The impacts of such estimates are pervasive throughout the financial statements and may require accounting adjustments based on future occurrences. Revisions to accounting estimates are recognized in the period in which the estimate is revised and future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions, and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Estimates and underlying assumptions are reviewed on an ongoing basis. The following are the key estimate and assumption uncertainties:

Warrants and stock options

Warrants and stock options are initially valued at fair value, based on the application of the Black-Scholes option pricing model. This pricing model requires management to make various assumptions and estimates which are susceptible to uncertainty, including the volatility of the share price, expected dividend yield, expected term of the warrant or stock option and expected risk-free interest rate.

Useful lives and impairment of long-lived assets

Long-lived assets are defined as property, plant, and equipment and intangible assets with finite lives. Depreciation and amortization are dependent upon estimates of useful lives and impairment is dependent upon estimates of recoverable amounts. These are determined through the exercise of judgment and are dependent upon estimates that consider factors such as economic and market conditions, frequency of use, anticipated changes in laws, and technological improvements. Refer to Notes 4 and 6.

Income taxes

Income taxes and tax exposures recognized in the consolidated financial statements reflect management's best estimate based on facts known at the reporting date. When the Company anticipates a future income tax payment based on its estimates, it recognizes a liability. The difference between the expected amount and the final tax outcome has an impact on current and deferred taxes when the Company becomes aware of this difference. In addition, when the Company incurs losses for income tax purposes, it assesses the probability of taxable income being available in the future based on its budgeted forecasts. These forecasts are adjusted to consider certain non-taxable income and expenses and specific rules on the use of unused credits and tax losses. When the forecasts indicate that sufficient future taxable income will be available to deduct the temporary differences, a deferred tax asset is recognized for all deductible temporary differences. Refer to Note 13.

Business combinations

In determining the appropriate basis of accounting for an acquisition, judgment is used to determine if an acquisition is a business combination or an asset acquisition. Refer to Note 4.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**2. SIGNIFICANT ACCOUNTING POLICIES - continued**

**(n) Recent and future accounting pronouncements**

Certain new standards, interpretations, amendments and improvements to existing standards were issued by the IASB or IFRIC that are mandatory for future accounting periods. Updates that are not applicable or are not consequential to the Company have been excluded.

IFRS 16 – Leases (“IFRS 16”)

IFRS 16 supersedes IAS 17 Leases, IFRIC 4 Determining whether an Arrangement contains a Lease, SIC-15 Operating Leases – Incentives and SIC-27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease. It eliminates the distinction between operating and finance leases from the perspective of the lessee. All contracts that meet the definition of a lease will be recorded in the statement of financial position with a “right of use” asset and a corresponding liability. The asset is subsequently accounted for as property, plant and equipment or investment property and the liability is unwound using the interest rate inherent in the lease.

The date of initial application of IFRS 16 is annual periods beginning on or after January 1, 2019. The Company has elected to adopt IFRS 16 using the modified retrospective approach. Under this approach, the Company will not restate its comparative figures but will recognize the cumulative effect of adopting IFRS 16 as an adjustment to opening retained earnings at the beginning of the 2020 fiscal year, September 1, 2019. The Company leases its head office building. At September 1, 2019, the Company’s office lease extends to September 30, 2020. On transition to IFRS 16, the Company elected to apply the practical expedient to grandfather the assessment of which transactions are leases and apply IFRS 16 only to contracts that were previously identified as leases. Contracts that were not identified as leases under IAS 17 Leases will not be reassessed for whether a lease exists. The Company will elect to not recognize right-of-use assets and lease liabilities for leases that have a lease term of 12 months or less and for leases of low-value assets. The Company will also account for leases for which the lease term ends within 12 months of the date of initial application as short-term leases. The impact of the adoption of IFRS 16 is disclosed in Note 7(d).

**3. FINANCIAL RISK FACTORS**

The Company’s risk exposure and the impact on its financial instruments are summarized below:

**Credit Risk**

Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment/contractual obligations. The Company has deposited its cash with reputable Canadian financial institutions, from which management believes the risk of loss is minimal.

**Liquidity Risk**

The Company’s approach to managing liquidity risk is to ensure that it has sufficient liquidity to meet liabilities when due. As at August 31, 2020, the Company has current assets of \$706,540 (August 31, 2019 - \$1,433,920) to settle current financial liabilities of \$6,190,260 (August 31, 2019 - \$407,007) (Note 1).

\$4,070,781 of the current financial liabilities relates to a mortgage on the Company’s investment property (Note 7(a)) which matures in February 2021. Discussions are underway to extend the term of the mortgage.

\$723,149 of the current financial liabilities relates to a mortgage on the Company’s Colombian property (Note 7(c)) which is to be fully repaid by May 2021.

Additional details relating to the repayment dates of the Company’s long-term debt are included in Note 7.

**Market Risk**

Market risk is the risk of loss that may arise from changes in market factors such as interest rates and commodity and equity prices.

Interest Rate Risk

The Company’s current policy is to invest excess cash in investment-grade short term deposit certificates issued by its banking institutions. The Company monitors the investments it makes and is satisfied with the credit ratings of its banks. The risk the Company will realize a loss as a result of a decline in the fair value of short-term deposits is limited due to the short-term nature of these investments.

The Company’s long-term debt carries a fixed rate of interest payable together with the principal at maturity.

Commodity Price Risk

The ability of the Company to develop its cannabis properties and hemp activities and the future profitability of the Company is directly related to the market price of cannabis and hemp.



**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**4. ACQUISITIONS**

COLOMBIA

On November 18, 2019 the Company, through its subsidiary Grupo LCG SAS, acquired a farm property in Carmen de Viboral, Colombia. The purchase price for the facility was 3.225 billion Colombian pesos (CAD \$1.29 million). The Company has determined that the assets acquired do not constitute a business under IFRS 3 Business Combinations and the transaction has been accounted for as an asset acquisition.

**Purchase Price:**

Present value of cash payments	\$	1,217,730
Acquisition costs		27,055
	<b>\$</b>	<b>1,244,785</b>

**Net Assets acquired:**

Land	\$	975,905
Buildings		268,870
	<b>\$</b>	<b>1,244,775</b>

See Note 7(c) for additional payment details.

WOODSTOCK BIOMED INC.

On June 18, 2018, the Company acquired 100% of the issued and outstanding shares of Woodstock Biomed Inc. ("Woodstock") in Pelham, Ontario. The 29.5-acre property (the "Property") was to serve as the Company's cornerstone for cannabis cultivation operations in Canada.

The acquisition of Woodstock Biomed was accounted for as an asset acquisition because it was determined that Woodstock did not meet the definition of a business under IFRS 3.

IN addition to other fixed payments, the purchase price included a \$750,000 cash payment contingent on receipt of a cultivation license for the facility and 10,000,000 common shares of the Company subject to an escrow agreement to be released if Woodstock receives its cultivation license prior to August 14, 2019. If the license is not received before August 14, 2019, these shares will be returned to the Company for cancellation.

On October 15, 2018, the Pelham Town Council imposed an interim control bylaw ("ICB") prohibiting any further development of all land within the Town for any type of cannabis cultivation and/or processing for up to one year.

On May 21, 2019, after extensive, good faith appeals to the Pelham Town Council for relief from the ICB, the Company's wholly-owned subsidiary Woodstock Biomed Inc. announced its intention to initiate legal action against the Town to mitigate the Company's damages as a result of Council's decision to uphold the ICB.

On September 23, 2019, the Town of Pelham Council voted in favour extending the ICB to July 15, 2020.

Woodstock was not awarded a cannabis cultivation and sales licence by Health Canada before August 14, 2019; therefore, the 10,000,000 contingently returnable common shares were cancelled, and the contingent cash payment was no longer payable. The value originally assigned to the contingent escrowed shares and the contingent cash payment of \$750,000 has been recorded as a gain in the consolidated statement of operations and comprehensive loss during the year ended August 31, 2019.

The material uncertainties attributable to the Town Council's imposition of its ICB and the outcome of any legal recourse were considered indicators of impairment in managements' annual assessment of the cash generating unit containing the licence-in-progress during the year ended August 31, 2019. As there was no reasonable expectation of being able to use the license in the future, management could not reliably determine any future cash-flows expected from the assets in either a value in use or a fair value less costs to sell model and, therefore, management fully impaired the License-in-Progress. This resulted in an impairment charge to the consolidated statement of operations and comprehensive loss in the year ended August 31, 2019 of \$23,314,616, net of the recoveries for the cancelled contingent cash and escrowed share payments.

<b>Impact on the year ended August 31, 2019</b>	<b>Amount</b>
Impairment of License-in-Progress	\$36,597,192
Recovery of contingent cash consideration	(674,806)
Recovery of contingent share deferred consideration (Note 8(a))	(12,607,770)
Impairment/disposal of associated property, plant and equipment (Note 6)	587,354
<b>Total impairment</b>	<b>\$23,901,970</b>

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

**5. INVESTMENT PROPERTY**

During the period, the Company executed a lease for the Woodstock property (Note 4) that was previously owner-occupied. The property was measured at cost until the change of use of the property to investment property. The Company measures the investment property at fair value. The fair value is based on a valuation by an independent valuer who holds a recognized and relevant professional qualification and has recent experience in the location and category of the investment property being valued. Operation costs of the investment property after its reclassification to investment property were approximately \$7,300.

The following is a reconciliation of the carrying value of the Company's investment property:

	2020	2019
Opening balance	\$ -	\$ -
Transfer from owner-occupied property	3,322,552	-
Expenditure recognized in the carrying value	654,585	-
Fair value adjustments	7,253	-
<b>Closing balance</b>	<b>\$ 3,984,390</b>	<b>\$ -</b>

**6. PROPERTY, PLANT AND EQUIPMENT**

	Assets under Construction	Right of Use Asset	Growing Equipment	Furniture	Total
<b>Cost</b>					
<b>At August 31, 2018</b>	<b>4,525,000</b>	<b>-</b>	<b>18,800</b>	<b>5,171</b>	<b>4,548,971</b>
Additions	1,084,741	-	-	-	1,084,741
Disposal	(1,205,000)	-	(8,800)	-	(1,213,800)
Impairment	(587,354)	-	-	-	(587,354)
<b>At August 31, 2019</b>	<b>3,817,387</b>	<b>-</b>	<b>10,000</b>	<b>5,171</b>	<b>3,832,558</b>
Adoption of IFRS 16	-	43,076	-	-	43,076
Transfer to investment property (Note 6)	(3,322,552)	-	(7,448)	-	(3,330,000)
Additions	2,886,306	-	1,949,445	108,738	4,944,489
Additions - right of use asset	-	57,966	-	-	57,966
Effect of foreign exchange	(248,231)	-	(59,659)	(3,943)	(311,833)
<b>At August 31, 2020</b>	<b>3,132,910</b>	<b>101,042</b>	<b>1,892,338</b>	<b>109,966</b>	<b>5,236,256</b>
<b>Accumulated Amortization</b>					
<b>At August 31, 2018</b>	<b>-</b>	<b>-</b>	<b>8,800</b>	<b>834</b>	<b>9,634</b>
Amortization for the period	-	-	2,108	1,301	3,409
Adjust for disposal	-	-	(4,534)	-	(4,534)
<b>At August 31, 2019</b>	<b>-</b>	<b>-</b>	<b>6,374</b>	<b>2,135</b>	<b>8,509</b>
Amortization for the period	-	39,602	1,675	1,301	42,578
Transfer to investment property (Note 6)	-	-	(7,448)	-	(7,448)
<b>At August 31, 2020</b>	<b>-</b>	<b>39,602</b>	<b>601</b>	<b>3,436</b>	<b>43,639</b>
<b>Net Book Value</b>					
At August 31, 2019	3,817,387	-	3,626	3,036	3,824,049
<b>At August 31, 2020</b>	<b>3,132,910</b>	<b>61,440</b>	<b>1,891,737</b>	<b>106,530</b>	<b>5,192,617</b>

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

**7. LONG-TERM DEBT**

The Company's long-term debt agreements are summarized below:

	<b>2020</b>	<b>2019</b>
Woodstock (a)	\$ 4,070,784	\$ 3,717,089
Bridge Loan (b)	5,234,642	-
Colombia Mortgage (c)	723,149	-
Lease Liability (d)	56,693	-
Government Loan (e)	40,000	-
	<b>\$ 10,125,268</b>	<b>\$ 3,717,089</b>
Less: current portion	4,830,158	-
	<b>\$ 5,295,110</b>	<b>\$ 3,717,089</b>

**a) Woodstock**

On the acquisition of Woodstock (Note 4), the Company inherited two mortgages of equal value and rank. Both mortgages bear interest of 7% per annum, compounded monthly. Interest is accumulated and repayable together with the principal on February 22, 2021 less any accumulated interest paid during the term.

	<b>2020</b>	<b>2019</b>
Opening balance	\$ 3,717,089	\$ 3,449,424
Interest expense	277,518	262,235
Accretion expense	76,180	64,071
Payments	-	(60,000)
<b>Closing balance</b>	<b>\$ 4,070,781</b>	<b>\$ 3,717,089</b>
Less: current portion	4,070,781	-
<b>Non-current portion</b>	<b>\$ -</b>	<b>\$ 3,717,089</b>

**b) Bridge Loan**

On October 15, 2019 the Company signed an agreement with a shareholder to provide unsecured financing of up to \$5,500,000 bearing interest at a rate of ten percent (10%) per annum from the date of each advance, payable three times per year: April 30, August 31, and December 31. The Company may, at its discretion, repay the balance of principal and/or interest owing at any time without penalty. In October 2020, the agreement was increased to \$7,500,000 (see Note 15). The Company determined that the interest rate was preferential and has discounted the future cash flows at an effective rate of 16%. The resulting discount on initial recognition is recognized directly in equity as a shareholder contribution.

	<b>2020</b>	<b>2019</b>
Opening balance	\$ -	\$ -
Draws (i)	5,568,082	-
Discount	(486,376)	-
Interest expense	285,589	-
Accretion expense	152,936	-
Payments (i)	(285,589)	-
<b>Closing balance</b>	<b>\$ 5,234,642</b>	<b>\$ -</b>

(i) Of the total interest expense of \$285,589, \$168,082 was not paid and has been treated as an additional draw.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

**7. LONG-TERM DEBT - continued**

**c) Colombia Mortgage**

On November 18, 2019 the Company, through its subsidiary Grupo LCG SAS, acquired a farm property located on 22.43 flat acres land in Carmen de Viboral, Colombia. The purchase price for the facility was 3.225 billion Colombian pesos (CAD \$1.29 million). The Company paid C\$429,000 during the period. A first ranking mortgage is secured against the property with an interest rate of 0.625% per month. The Company discounted the future principal and interest payments using an effective rate of 13.39%.

	<b>2020</b>	<b>2019</b>
Opening balance	\$ 1,285,730	\$ -
Discount	(68,000)	-
Interest expense	44,835	-
Accretion expense	43,735	-
Payments	(462,960)	-
Effect of changes in foreign exchange rates	(120,191)	-
<b>Closing balance</b>	<b>\$ 723,149</b>	<b>\$ -</b>
Less: current portion	723,149	-
<b>Non-current portion</b>	<b>\$ -</b>	<b>\$ -</b>

As at August 31, 2020, the remaining principal payments are COL \$1,250,000,000 (CAD \$436,250) on December 9, 2020 and COL \$860,000,000 (CAD \$300,140) on June 9, 2021.

**d) Lease Liability**

Upon adoption of IFRS 16 Leases on September 1, 2019, a lease liability of \$36,228 was recognized, prepaid lease payments of \$6,848 were derecognized, and a right of use asset of 43,076 was recognized. The following is a summary of the impact of the adoption of IFRS 16:

	<b>September 1, 2019</b>	<b>August 31, 2019</b>
<b>Assets</b>		
Prepaid expenses	\$ 59,771	\$ 66,619
Property, plant, and equipment, net	3,867,125	3,824,049
	<b>\$ 3,926,896</b>	<b>\$ 3,890,668</b>
<b>Liabilities</b>		
Current portion of long-term debt	\$ 36,228	\$ -
	<b>\$ 36,228</b>	<b>\$ -</b>

During the period, the lease was extended and the liability and right of use asset were both increase by \$57,966. The following is a reconciliation of the lease liability:

	<b>2020</b>	<b>2019</b>
Opening balance	\$ -	\$ -
Adoption of IFRS 16	36,228	-
Extension of lease	57,966	-
Interest expense	1,876	-
Lease payments	(39,377)	-
<b>Closing balance</b>	<b>\$ 56,693</b>	<b>\$ -</b>
Less: Current portion	39,129	-
<b>Non-current portion</b>	<b>\$ 17,564</b>	<b>\$ -</b>

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**7. LONG-TERM DEBT - continued**

**e) Government Loan**

During the period, the Company received a \$40,000 loan from Canada Emergency Business Account (“CEBA”). This interest free loan was offered by the Canadian Government through the Corporation’s bank in the context of the Covid-19 pandemic outbreak to finance operating costs. Repayment of the loan balance on or before December 31, 2022 will result in a loan forgiveness of \$10,000. As at January 1st, 2023, the Corporation will have the option to extend the repayment of the capital for 3 years and will benefit from an interest rate of 5%.

**8. SHARE CAPITAL AND RESERVES**

**a. Share Capital**

**Authorized:**

Unlimited number of common shares.

**Issued and outstanding:**

84,743,603 (2019 – 84,743,603)

**Escrow:**

Nil (2019 – 14,000,000)

**Activity:**

Fiscal 2019

In September 2018, the Company issued a total of 3,972,002 Units for \$0.50 per Unit for total cash proceeds of \$1,986,001 including the \$25,000 received in August 2018. Each unit comprised one common share and one common share purchase warrant exercisable at \$1.00 for 24 months.

The warrants were allocated net proceeds of \$655,380 based on the same relative fair value within the Unit as determined in the August 2018 financing (Note 8(c)).

As set out in the Woodstock purchase agreement, 10,000,000 of the shares issued in escrow were contingently returnable subject to terms and conditions to be satisfied by August 14, 2019. These conditions were not met by August 14, 2019 and the Company commenced cancellation the shares. The \$12,607,770 fair value originally assigned to these shares was recorded as a recovery during the year (Note 4). The cancellation of the escrowed shares was formally completed on September 16, 2019.

Fiscal 2020

No activity.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**8. SHARE CAPITAL AND RESERVES – continued**

**b. Stock options**

The Company has a stock option plan (the "Plan") under which the directors of the Company may grant options to qualified directors, officers, employees and consultants of the Company. The exercise price of the options cannot be less than the closing price of the Company's shares on the trading day preceding the date of grant and the maximum term of any option cannot exceed five years. The maximum aggregate number of common shares under option at any time under the Plan cannot exceed 10% of the issued and outstanding common shares.

**Activity:**

Fiscal 2019

On October 2, 2018, the Company granted 400,000 options to a director exercisable at \$1.50, vesting quarterly, in-advance, over two years, and expiring two years after vesting. The value of the options was determined to be \$336,679 using 90% volatility, 2 to 3.75-year expected life, 1.63% discount rate, and \$Nil expected dividend. The director subsequently resigned from the board on November 8, 2018, thus forfeiting 350,000 options unvested. On February 6, 2019, the remaining 50,000 were cancelled.

On November 8, 2018, the Company granted 600,000 options to two directors exercisable at \$0.60, vesting quarterly, in-advance, over two years, and expiring two years after vesting. The value of the options was determined to be \$189,561 using 90% volatility, 2 to 3.75-year expected life, 2.37% discount rate, and \$Nil expected dividend.

On January 11, 2019, the Company granted 150,000 options to an employee exercisable at \$0.60, vesting annually over two years, and expiring two years after vesting. The value of the options was determined to be \$36,392 using 90% volatility, 3 to 4-year expected life, 2.37% discount rate, and \$Nil expected dividend. The employee left the Company on July 15, 2019 thus forfeiting the options.

On April 1, 2019, 150,000 options issued to a consultant on July 25, 2018 exercisable at \$1.53 were cancelled. On the same day, the Company granted a company owned by the same consultant 150,000 options, vesting immediately, exercisable at \$0.60 per common share until April 1, 2021. These transactions were treated as an option modification for accounting purposes. The incremental Black-Scholes value of \$7,306 along with the previously unvested value of \$104,366 was expensed immediately. The Black-Scholes valuations used the following assumptions:

	Original	Modified
Stock price	\$0.30	\$0.30
Exercise price	\$1.53	\$0.60
Expected life	1.5 to 3.0 years	2 years
Volatility	90%	90%
Dividend yield	0%	0%
Risk-free rate	2.05%	2.05%

On May 10, 2019, the Company granted an executive engineering consultant 200,000 options exercisable at \$0.60, vesting immediately, and expiring two years from grant. The value of the options was determined to be \$50,735 using 90% volatility, 2-year expected life, 1.64% discount rate and \$Nil expected dividend.

On May 22, 2019, the Company granted a senior US operations and processing consultant 200,000 options exercisable at \$0.60, vesting quarterly, in-advance, over two years, and expiring two years after vesting. The value of the options was determined to be \$58,067 using 90% volatility, 2 to 3.75-year expected life, 1.66% discount rate and \$Nil expected dividend.

The total share-based compensation during the year ended August 31, 2019 is \$353,054.

Fiscal 2020

On November 14, 2019, 300,000 options issued to a former employee expired.

On November 20, 2019, 300,000 options issued to a former employee expired.

The total share-based compensation during the year ended August 31, 2020 is \$60,354.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

**8. SHARE CAPITAL AND RESERVES - continued**

**b. Stock options - continued**

A summary of the Company's stock option activity for the years ended August 31, 2020 and 2019 is as follows:

	Number of Options	Weighted-Average Exercise Price (\$)
Outstanding, August 31, 2018	9,200,000	1.18
Granted	1,550,000	0.60
Cancelled/Expired	(3,640,640)	1.30
Outstanding, August 31, 2019	7,109,360	0.69
Cancelled/Expired	(1,359,360)	2.00
Outstanding, August 31, 2020	5,750,000	0.60

The weighted average remaining contractual life and weighted average exercise price of options outstanding and of options exercisable as at August 31, 2020 are as follows:

Date of Grant	Exercise Price (\$)	Number Outstanding	Number Exercisable	Remaining Life (Years)
May 18, 2018	0.60	4,600,000	4,600,000	0.72
July 25, 2018	0.60	150,000	150,000	0.64
November 8, 2018 (i)	0.60	600,000	300,000	0.19
May 10, 2019	0.60	200,000	200,000	0.69
May 22, 2019	0.60	200,000	150,000	0.73
		5,750,000	5,700,000	

(i) Expired on November 20, 2020

**c. Warrants**

Between June 2018 and September 2018, the Company issued 15,000,000 share purchase warrants as part of a \$0.50 per unit private placement financing. Each warrant entitles the holder thereof to purchase one common share at an exercise price of \$1.00 per common share for 24 months. The Company may require the holders of the Warrants, upon 15 days' notice, to exercise their right to purchase common shares at any time after 120 days from July 9, 2018, if the common shares close at or above \$1.50 per common share for 20 consecutive trading days.

The value of a warrant was determined using 90% volatility, 2-year expected life, 1.94% discount rate, 0% expected dividend. The resulting value represented approximately 33% of the value of the Unit with the remaining 67% attributed to the value of the common share within the Unit. The warrants were allocated \$2,477,380 of the net proceeds of the financing.

On June 19, 2020, the Company repriced and extended the expiry date of the 15,000,000 share purchase warrants expiring between July 2020 and September 2020. The warrants were repriced from \$1.00 to \$0.75 and the expiry date extended to December 31, 2020. All other terms of the warrants remain unchanged. (See Note 15 – Subsequent Events)

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**9. INTEREST IN SUBSIDIARIES**

These consolidated financial statements incorporate the activities of the Company's subsidiaries from the date the Company acquires control to the date control is relinquished.

The Company's subsidiaries and relative ownership interests are as follows:

<b>Subsidiary</b>	<b>Domicile</b>	<b>Ownership Interest</b>	<b>Date Control Acquired</b>
Bathurst Resources Corp.	Canada	100%	December 31, 2013
Jekyll and Hyde Brand Builders Inc.	Canada	100%	December 22, 2017
Woodstock Biomed Inc.	Canada	100%	August 14, 2019
Leviathan US, Inc. (90%)	USA	90%	April 15, 2019
LCG Holdings Inc. (65%) (i)	Canada	65%	August 1, 2019
Grupo LCG SAS	Colombia	65% (ii)	August 21, 2019

(i) The Company has established LCG Holdings Inc. as a business venture to cultivate hemp and manufacture cannabidiol ("CBD") isolate and other extracted products in the rich agricultural region of Republic of Colombia, South America.

(ii) A 100% interest of Grupo LCG SAS is held through LCG Holdings Inc.

**10. LOSS PER SHARE**

The calculation of basic and diluted loss per share for the year ended August 31, 2020 was based on the net loss and comprehensive loss attributable to common shareholders of \$2,817,606 (2019 – \$28,528,627) and the weighted average number of common shares outstanding of 84,743,903 (2019 – 84,743,903).

**11. RELATED PARTY BALANCES AND TRANSACTIONS**

The remuneration expense of directors and other members of key management personnel, or companies under their control, are as follows:

	<b>2020</b>	<b>2019</b>
Salaries, consulting and benefits	\$ 409,963	\$ 588,000
Share based compensation	60,354	353,054
	<b>\$ 470,317</b>	<b>\$ 941,054</b>

\$Nil (2019 - \$48,253) of the Company's revenue was from a company controlled by a director of the Company.

\$Nil (2019 - \$39,000) of the Company's revenue was from a company controlled by a director of the Company.

During the period, US\$941,507 (August 31, 2019 – US\$Nil) was paid to a company controlled by a shareholder of one of the Company's subsidiaries, for the renovation and build out of the Company's growing facility in Tennessee.



**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

**12. OPERATING SEGMENTS**

The Company currently operates in three business segments:

- 1) Cannabis focused marketing services (“Marketing”);
- 2) Cultivation, processing, and distribution of cannabis and hemp products in Canada and hemp products in the United States & South America (“Cultivation”). As at August 31, 2020, 100% of the Company’s cultivation operations are in the development stage; and
- 3) Investment Property (“Investment”).

The Company manages its reporting segments based on a combination of geographic and operational information as follows:

	Corporate	Cultivation				Marketing	Investment	Total
	Canada	Canada	USA	Colombia	Total Cultivation	Canada	Canada	
Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 72,732	\$ 72,732
Share-based compensation	60,354	-	-	-	-	-	-	60,354
Interest expense (income)	438,590	206,260	3,589	93,276	303,125	1,901	147,329	890,945
Amortization	-	1,075	-	600	1,675	40,903	-	42,578
All other expenses	1,076,266	39,003	605,614	334,323	978,940	52,450	-	2,107,656
<b>Net Loss</b>	<b>\$ (1,575,210)</b>	<b>\$ (246,338)</b>	<b>\$ (609,203)</b>	<b>\$ (428,199)</b>	<b>\$ (1,283,740)</b>	<b>\$ (95,254)</b>	<b>\$ (74,597)</b>	<b>\$ (3,028,801)</b>
Current Assets	440,095	89,506	80,156	8,217	177,879	88,566	-	706,540
Investment property	-	-	-	-	-	-	3,984,390	3,984,390
Property, plant, and equipment	-	-	4,008,880	1,120,562	5,129,442	63,175	-	5,192,617
<b>Total Assets</b>	<b>\$ 440,095</b>	<b>\$ 89,506</b>	<b>\$ 4,089,036</b>	<b>\$ 1,128,779</b>	<b>\$ 5,307,321</b>	<b>\$ 151,741</b>	<b>\$ 3,984,390</b>	<b>\$ 9,883,547</b>
Current liabilities	503,319	11,471	254,365	754,257	1,020,093	14,211	4,652,637	6,190,260
Intercompany payable (receivable)	(8,163,108)	2,724,100	4,333,371	914,528	7,971,999	191,109	-	-
Long-term debt	5,274,642	-	-	-	-	20,468	-	5,295,110
<b>Total liabilities</b>	<b>\$ (2,385,147)</b>	<b>\$ 2,735,571</b>	<b>\$ 4,587,736</b>	<b>\$ 1,668,785</b>	<b>\$ 8,992,092</b>	<b>\$ 225,788</b>	<b>\$ 4,652,637</b>	<b>\$ 11,485,370</b>

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

**13. INCOME TAXES**

Income tax comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income.

Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted at the end of the reporting period, and any adjustment to tax payable in respect of previous years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company intends to settle on a net basis, or to realize the asset and settle the liability simultaneously.

Deferred tax is recognized in respect of all qualifying temporary differences arising between the tax basis of assets and liabilities and their carrying amounts in the financial statements. Deferred income tax is determined on a non-discounted basis using tax rates and laws that have been enacted or substantively enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are recognized to the extent that it is probable that the assets can be recovered. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.

Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the final outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.

The reconciliation of the combined Canadian federal and provincial statutory income taxes rate of 26.5% (2019 – 26.5%) to the effective tax rate is as follows:

	<b>2020</b>	<b>2019</b>
Net loss before recovery of income taxes	\$ (3,028,801)	\$ (28,562,047)
Expected income tax (recover) expense	(802,630)	(7,568,940)
Tax rate changes and other adjustments	21,930	9,920
Non-deductible expenses	71,700	101,840
Stock based compensation	15,990	93,560
Impairment of assets	-	6,334,020
Change in tax benefits not recognized	693,010	1,029,600
Income tax (recovery)	\$ -	\$ -

**Deferred tax**

Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset. The following table summarizes the components of deferred tax:

	<b>2020</b>	<b>2019</b>
Deferred tax assets		
Capital lease obligations	\$ 15,020	-
Operating tax losses carried forward	1,260	-
	<b>\$ 16,280</b>	<b>\$ -</b>
Deferred tax liabilities		
Right of Use Asset	(16,280)	-
	<b>\$ 16,280</b>	<b>\$ -</b>
Income tax (recovery)	\$ -	\$ -

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**13. INCOME TAXES - continued**

**Unrecognized Deferred Tax Assets**

Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amount of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences because it is not probable that future taxable profit will be available against which the Company can utilize the benefits therefrom:

	<b>2020</b>	<b>2019</b>
Property, plant and equipment	\$ 10,630	\$ 1,217,860
Investment property	1,070,320	-
Long-term debt	10,000	-
Investment	376,050	-
Share issuance costs	14,220	21,330
Operating tax losses – Canada	9,464,550	6,549,360
Operating tax losses – U.S.	738,340	-
Capital loss carried forward	50,000	50,000

The Canadian operating tax losses expire as noted in the table below. The U.S. operating tax losses can be carried forward indefinitely. Share issuance costs will be fully amortized in 2022. The capital losses may be carried forward indefinitely but can only be used to reduce capital gains. The share issuance costs will be fully deducted by 2022. The remaining deductible temporary differences may be carried forward indefinitely.

The Company's Canadian non-capital income tax losses expire as follows:

2031	\$ 107,220
2032	276,270
2033	344,090
2034	287,440
2035	279,050
2036	376,150
2037	1,224,130
2038	1,371,900
2039	3,159,960
2040	2,038,360
	<b>\$ 9,464,550</b>

**14. CONTINGENCIES**

The Company has been charged under section 24 of the Provincial Offences Act for allegedly violating the Town of Pelham's Cannabis Interim Control Bylaw (ICB). If found guilty under section 67 of the Planning Act there may be a maximum fine of \$50,000 for a first conviction, a surcharge to any fine of up to 25% of the fine amount, and, in some cases, a special fine may arise if there was an economic gain obtained due to the violation in an amount of the economic gain. Any potential liability cannot be reliably estimated and no provision has been recorded in these consolidated financial statements.

The Company has initiated legal proceedings against of the Town of Pelham. This litigation, filed through the Ontario Superior Court of Justice, follows the Town of Pelham Council's decision to deny the Company an exemption to its Interim Control By-law (4046), which placed a one-year moratorium on the building of new cannabis facilities and the expansion of existing operations.

The Company, along with two other cannabis companies operating in the Town of Pelham, appealed to the Local Planning Appeal Tribunal regarding the Town of Pelham's amendments to its agricultural zoning by-law and official plan following its land review study of cannabis cultivation and processing issues.

**LEVIATHAN NATURAL PRODUCTS INC.**  
**(FORMERLY LEVIATHAN CANNABIS GROUP INC.)**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE YEARS ENDED AUGUST 31, 2020 AND 2019**

---

**15. SUBSEQUENT EVENTS**

On October 5, 2020, the Company increased the value of a debt facility described in Note 7(b) from \$5.5 million to \$7.5 million on the same terms and conditions as the original agreement.

On December 11, 2020, the Company repriced and extended the expiry date of an aggregate of 15,000,000 outstanding private placement warrants expiring in December 2020. The warrants were originally issued pursuant to a private placement financing that closed in several tranches in July 2018, and were originally set to expire in July 2020. The warrants were extended and repriced on June 19, 2020. On December 8, 2020, the CSE granted Leviathan an exemption which allowed the Company to conduct a second repricing and extension of the warrants. The warrants will be repriced from \$0.75 to \$0.60 and the expiry date extended to December 31, 2021. All other terms of the warrants remain unchanged.